Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Sara A. Hurvitz, MD, FACP, Michelle Melisko, MD, and Paolo Tarantino, MD, PhD, discuss approaches to maintenance and subsequent lines of therapy for patients with HER2+ advanced breast cancer, including those with CNS metastases.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss current and emerging frontline and maintenance options for the management of HER2+ mBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Pfizer, Inc.

Chair:

Sara A. Hurvitz, MD, FACP

Professor of Medicine Head, Division of Hematology and Oncology
University of Washington Medicine
Senior Vice President, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ALX Oncology, Bayer, BeiGene, Briacell, Bridge Biooncology, Bristol Meyers Squibb, Daiichi Sanko, EMBiosys, Eli Lilly, Gilead, Jazz, Luminate, Mersana, Novartis, Prelude Therapeutics, Roche/Genentech; Grant/Research Funding: Novartis, Stemline/Menari, Daiichi Sankyo/TRIO

Faculty:

Michelle Melisko, MD

Clinical Professor of Medicine
Department of Medicine
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Genentech; Grant/Research Funding: Gilead, KCRN Research, Novartis, OBI Pharma, Pfizer, Puma, Stemline Therapeutics

Paolo Tarantino, MD, PhD

Clinical Fellow Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Menarini/Stemline, Novartis, Roche; Grant/Research Funding: AstraZeneca

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on adjuvant treatment of early stage EGFR-mutant non-small cell lung cancer and targeting resistance mechanisms in metastatic disease, go to https://www.gotoper.com/sabcs25her2maintenance-enduring.

Release Date

January 16, 2026

Expiration Date

January 16, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.